Lantheus To Present Additional Clinical Data From Phase 3 Pivotal SPLASH Trial In PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress In Barcelona On Sunday, September 15, 2024

Author: Benzinga Newsdesk | August 20, 2024 08:58am

Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that Oliver Sartor, MD, Director of Radiopharmaceutical Trials and Professor of Medical Oncology at the Mayo Clinic in Rochester, Minnesota, will deliver an oral presentation, including additional clinical data from PNT2002's initial December 2023 readout, during the European Society of Medical Oncology (ESMO) Annual Meeting in Barcelona on Sunday, September 15, 2024.
 

Posted In: LNTH